NM-IL-12 + PD-1 inhibitor

NM-IL-12 + PD-1 inhibitor is a preclinical-stage combination immunotherapy asset in the pipeline of Libo Pharma, a Taiwanese biopharmaceutical company. The combination pairs NM-IL-12 — Libo Pharma's proprietary novel large-molecule protein immunotherapy targeting the interleukin-12 (IL-12) pathway — with an unspecified programmed cell death protein 1 (PD-1) inhibitor. The scientific rationale for this combination is that IL-12 signaling and PD-1 blockade act synergistically to boost T cell-mediated anti-tumor immunity, potentially overcoming resistance to single-agent checkpoint inhibitors. It is being developed for applications in oncology and hematology indications.

Other names

NM-IL-12 with PD-1 inhibitorNM-IL12 with PD-1 inhibitorNM-IL 12 with PD-1 inhibitor